Skip to main content
Erschienen in:

05.02.2022 | Original Paper

Oxalobacter formigenes treatment confers protective effects in a rat model of primary hyperoxaluria by preventing renal calcium oxalate deposition

verfasst von: A. Verhulst, B. Dehmel, E. Lindner, M. E. Akerman, P. C. D’Haese

Erschienen in: Urolithiasis | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

In primary hyperoxaluria, increased hepatic oxalate production sometimes leads to severe nephrocalcinosis and early end-stage kidney disease. Oral administration of Oxalobacter formigenes (O. formigenes), an oxalate-degrading bacterium, is thought to derive oxalate from systemic sources by inducing net enteric oxalate secretion. Here, the impact of O. formigenes on nephrocalcinosis was investigated in an ethylene glycol rat model mimicking hepatic oxalate overproduction in primary hyperoxaluria. Eighteen rats were administered ethylene glycol (0.75% in drinking water) for 6 weeks, of which 9 were treated by oral gavage with O. formigenes and 9 received vehicle. Five control rats did not receive ethylene glycol or O. formigenes. Plasma and urinary oxalate levels, calcium oxalate crystalluria, urinary volume, fluid intake, and serum creatinine were monitored during the study. On killing, nephrocalcinosis was quantified. Ethylene glycol intake induced pronounced hyperoxalemia, hyperoxaluria, calcium oxalate crystalluria and nephrocalcinosis. Concomitant O. formigenes treatment partially prevented the ethylene glycol-induced increase in plasma oxalate and completely prevented nephrocalcinosis. Urinary oxalate excretion was not reduced by O. formigenes treatment. Nevertheless, absence of crystals in renal tissue of O. formigenes-treated ethylene glycol animals indicates that the propensity for oxalate to crystallize in the kidneys was reduced compared to non-treated animals. This is supported by the lower plasma oxalate concentrations in O. formigenes-treated animals. This study shows a beneficial effect of O. formigenes treatment on ethylene glycol-induced hyperoxalemia and nephrocalcinosis, and thus supports a possible beneficial effect of O. formigenes in primary hyperoxaluria.
Literatur
1.
Zurück zum Zitat Vaidya SR, Aeddula NR (2020) Nephrocalcinosis. StatPearls, Treasure Island (StatPearls Publishing Copyright©2020, StatPearls Publishing LLC) Vaidya SR, Aeddula NR (2020) Nephrocalcinosis. StatPearls, Treasure Island (StatPearls Publishing Copyright©2020, StatPearls Publishing LLC)
2.
Zurück zum Zitat Buysschaert B, Aydin S, Morelle J, Gillion V, Jadoul M, Demoulin N (2020) Etiologies, clinical features, and outcome of oxalate nephropathy. Kidney Int Rep 5:1503–1509CrossRef Buysschaert B, Aydin S, Morelle J, Gillion V, Jadoul M, Demoulin N (2020) Etiologies, clinical features, and outcome of oxalate nephropathy. Kidney Int Rep 5:1503–1509CrossRef
3.
Zurück zum Zitat Cochat P, Rumsbey G (2013) Primary hyperoxaluria. N Eng J Med 396:649–658CrossRef Cochat P, Rumsbey G (2013) Primary hyperoxaluria. N Eng J Med 396:649–658CrossRef
4.
Zurück zum Zitat Garrelfs SF, Rumsby G, Peters-Sengers H, Erger F, Groothoff JW, Beck BB et al (2019) Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. Kidney Int 96:1389–1399CrossRef Garrelfs SF, Rumsby G, Peters-Sengers H, Erger F, Groothoff JW, Beck BB et al (2019) Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. Kidney Int 96:1389–1399CrossRef
5.
Zurück zum Zitat Martin-Higueras C, Garrelfs SF, Groothoff JW, Jacob DE, Moochhala SH, Bacchetta J et al (2021) A report from the European hyperoxaluria consortium (OxalEurope) registry on a large cohort of patients with primary hyperoxaluria type 3. Kidney Int 100:621–635CrossRef Martin-Higueras C, Garrelfs SF, Groothoff JW, Jacob DE, Moochhala SH, Bacchetta J et al (2021) A report from the European hyperoxaluria consortium (OxalEurope) registry on a large cohort of patients with primary hyperoxaluria type 3. Kidney Int 100:621–635CrossRef
7.
Zurück zum Zitat Lumlertgul N, Siribamrungwong M, Jaber BL, Susantitaphong P (2018) Secondary oxalate nephropathy, a systematic review. Kidney Int Rep 3:1363–1372CrossRef Lumlertgul N, Siribamrungwong M, Jaber BL, Susantitaphong P (2018) Secondary oxalate nephropathy, a systematic review. Kidney Int Rep 3:1363–1372CrossRef
8.
Zurück zum Zitat Robijn S, Hoppe B, Vervaet B, D’Haese P, Verhulst A (2011) Hyperoxaluria: a gut-kidney axis? Kidney Int 80:1146–1158CrossRef Robijn S, Hoppe B, Vervaet B, D’Haese P, Verhulst A (2011) Hyperoxaluria: a gut-kidney axis? Kidney Int 80:1146–1158CrossRef
9.
Zurück zum Zitat Milliner DS, McGregor TL, Thompson A, Dehmel B, Knight J, Rosskamp R, et al (2020) Endpoints for Clinical Trials in Primary Hyperoxaluria. Clin J Am Soc Nephrol 15(7):1056–1065 Milliner DS, McGregor TL, Thompson A, Dehmel B, Knight J, Rosskamp R, et al (2020) Endpoints for Clinical Trials in Primary Hyperoxaluria. Clin J Am Soc Nephrol 15(7):1056–1065
10.
Zurück zum Zitat Frishberg Y, Deschênes G, Groothoff JW, Hulton S-A, Magen D, Harambat J et al (2021) Phase 1/2 study of lumasiran for treatment of primary hyperoxaluria type 1: a placebo-controlled randomized clinical trial. Clin J Am Soc Nephrol 16:1025–1036CrossRef Frishberg Y, Deschênes G, Groothoff JW, Hulton S-A, Magen D, Harambat J et al (2021) Phase 1/2 study of lumasiran for treatment of primary hyperoxaluria type 1: a placebo-controlled randomized clinical trial. Clin J Am Soc Nephrol 16:1025–1036CrossRef
11.
Zurück zum Zitat Allison MJ, Dawson KA, Mayberry WR, Foss JG (1985) Oxalobacter formigenes gen. nov., sp. nov.: oxalate-degrading anaerobes that inhabit the gastrointestinal tract. Arch Microbiol 141:1–7CrossRef Allison MJ, Dawson KA, Mayberry WR, Foss JG (1985) Oxalobacter formigenes gen. nov., sp. nov.: oxalate-degrading anaerobes that inhabit the gastrointestinal tract. Arch Microbiol 141:1–7CrossRef
12.
Zurück zum Zitat Kaufman DW, Kelly JP, Curhan GC, Andererson TE, Dretler SP, Preminger GM (2008) Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol 19:1179–1203CrossRef Kaufman DW, Kelly JP, Curhan GC, Andererson TE, Dretler SP, Preminger GM (2008) Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol 19:1179–1203CrossRef
13.
Zurück zum Zitat Sidhu H, Allison M, Chow JW, Clark A, Peck AB (2001) Rapid reversal of hyperoxaluria in a rat model after probiotic administration of oxalobacter formigenes. J Urol 166:1487–1491CrossRef Sidhu H, Allison M, Chow JW, Clark A, Peck AB (2001) Rapid reversal of hyperoxaluria in a rat model after probiotic administration of oxalobacter formigenes. J Urol 166:1487–1491CrossRef
14.
Zurück zum Zitat Canales BK, Hatch M (2017) Oxalobacter formigenes colonization normalizes oxalate excretion in a gastric bypass model of hyperoxaluria. Surg Obesity Rel Dis 13:1152–1157CrossRef Canales BK, Hatch M (2017) Oxalobacter formigenes colonization normalizes oxalate excretion in a gastric bypass model of hyperoxaluria. Surg Obesity Rel Dis 13:1152–1157CrossRef
15.
Zurück zum Zitat Hatch M, Gjymishka A, Salido EC, Allison M, Freel RW (2011) Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with oxalobacter. Am J Physiol 300:G461–G469 Hatch M, Gjymishka A, Salido EC, Allison M, Freel RW (2011) Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with oxalobacter. Am J Physiol 300:G461–G469
16.
Zurück zum Zitat Hatch M, Cornelius JG, Allison M, Sidhu H, Peck AB, Freel RW (2006) Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int 69:1–8CrossRef Hatch M, Cornelius JG, Allison M, Sidhu H, Peck AB, Freel RW (2006) Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int 69:1–8CrossRef
17.
Zurück zum Zitat Arvans D, Jung YC, Antonopoulos D, Koval J, Granja I, Bashir M (2017) Oxalobacter formigenes-derived bioactive factors stimulate oxalate transport by intestinal epithelial cells. J Am Soc Nephrol 28:876–887CrossRef Arvans D, Jung YC, Antonopoulos D, Koval J, Granja I, Bashir M (2017) Oxalobacter formigenes-derived bioactive factors stimulate oxalate transport by intestinal epithelial cells. J Am Soc Nephrol 28:876–887CrossRef
18.
Zurück zum Zitat Wolthers BG, Hayer M (1982) The determination of oxalic acid in plasma and urine by means of capillary gas chromatography. Clin Chim Acta 120:87–102CrossRef Wolthers BG, Hayer M (1982) The determination of oxalic acid in plasma and urine by means of capillary gas chromatography. Clin Chim Acta 120:87–102CrossRef
19.
Zurück zum Zitat Robijn S, Vervaet BA, Hoppe B, D’Haese PC, Verhulst A (2013) Lanthanum carbonate inhibits intestinal oxalate absorption and prevents nephrocalcinosis after oxalate loading in rats. J Urol 189:1960–1966CrossRef Robijn S, Vervaet BA, Hoppe B, D’Haese PC, Verhulst A (2013) Lanthanum carbonate inhibits intestinal oxalate absorption and prevents nephrocalcinosis after oxalate loading in rats. J Urol 189:1960–1966CrossRef
20.
Zurück zum Zitat Daims H, Brühl A, Amann R, Schleifer KH, Wagner M (1999) The domain-specific probe EUB338 is insufficient for the detection of all bacteria: development and evaluation of a more comprehensive probe set. Syst Applied Microbiol 22:434–444CrossRef Daims H, Brühl A, Amann R, Schleifer KH, Wagner M (1999) The domain-specific probe EUB338 is insufficient for the detection of all bacteria: development and evaluation of a more comprehensive probe set. Syst Applied Microbiol 22:434–444CrossRef
21.
Zurück zum Zitat Snaidr J, Amann R, Huber I, Ludwig W, Schleifer KH (1997) Phylogenetic analysis and in situ identification of bacteria in activated sludge. Appl Environ Microbiol 63:2884–2896CrossRef Snaidr J, Amann R, Huber I, Ludwig W, Schleifer KH (1997) Phylogenetic analysis and in situ identification of bacteria in activated sludge. Appl Environ Microbiol 63:2884–2896CrossRef
22.
Zurück zum Zitat Green ML, Freel RW, Hatch M (2005) Lipid peroxidation is not the underlying cause of renal injury in hyperoxaluric rats. Kidney Int 68:2629–2638CrossRef Green ML, Freel RW, Hatch M (2005) Lipid peroxidation is not the underlying cause of renal injury in hyperoxaluric rats. Kidney Int 68:2629–2638CrossRef
23.
Zurück zum Zitat Li Y, McMartin KE (2009) Strain differences in urinary factors that promote calcium oxalate crystal formation in the kidneys of ethylene glycol-treated rats. Am J Physiol Renal Physiol 296:F1080–F1087CrossRef Li Y, McMartin KE (2009) Strain differences in urinary factors that promote calcium oxalate crystal formation in the kidneys of ethylene glycol-treated rats. Am J Physiol Renal Physiol 296:F1080–F1087CrossRef
24.
Zurück zum Zitat Marengo SR, Chen DH, Kaung HL, Resnick MI, Yang L (2002) Decreased renal expression of the putative calcium oxalate inhibitor Tamm–Horsfall protein in the ethylene glycol rat model of calcium oxalte urolithiasis. J Urol 167:2192–2197CrossRef Marengo SR, Chen DH, Kaung HL, Resnick MI, Yang L (2002) Decreased renal expression of the putative calcium oxalate inhibitor Tamm–Horsfall protein in the ethylene glycol rat model of calcium oxalte urolithiasis. J Urol 167:2192–2197CrossRef
25.
Zurück zum Zitat Khan SR, Thamilselvan S (2000) Nephrolithiasis: a consequence of renal epithelial cell exposure to oxalate and calcium oxalate crystals. Mol Urol 4:305–312PubMed Khan SR, Thamilselvan S (2000) Nephrolithiasis: a consequence of renal epithelial cell exposure to oxalate and calcium oxalate crystals. Mol Urol 4:305–312PubMed
26.
Zurück zum Zitat Lyon ES, Borden TA, Vermeulen CW (1966) Experimental oxalate lithiasis produced with ethylene glycol. Invest Urol 4:143–151PubMed Lyon ES, Borden TA, Vermeulen CW (1966) Experimental oxalate lithiasis produced with ethylene glycol. Invest Urol 4:143–151PubMed
27.
Zurück zum Zitat Asselman M, Verhulst A, De Broe ME, Verkoelen CF (2004) Calcium oxalate crystal adherence to hyaluronan-, osteopontin- and CD44-expressing injured/regenerating tubular epithelial cells in rat kidneys. J Am Soc Nephrol 2003(13):3155–3266 Asselman M, Verhulst A, De Broe ME, Verkoelen CF (2004) Calcium oxalate crystal adherence to hyaluronan-, osteopontin- and CD44-expressing injured/regenerating tubular epithelial cells in rat kidneys. J Am Soc Nephrol 2003(13):3155–3266
28.
Zurück zum Zitat Vervaet B, D’Haese P, De Broe M, Verhulst A (2009) Crystalluric and tubular epithelial parameters during the onset of intratubular nephrocalcinosis: illustration of the ‘fixed particle’ theory in vivo. Nephrol Dial Transplant 24:3659–3688CrossRef Vervaet B, D’Haese P, De Broe M, Verhulst A (2009) Crystalluric and tubular epithelial parameters during the onset of intratubular nephrocalcinosis: illustration of the ‘fixed particle’ theory in vivo. Nephrol Dial Transplant 24:3659–3688CrossRef
29.
Zurück zum Zitat Bashir S, Gilani AH, Siddiqui AA, Pervez S, Khan SR, Sarfaraz NJ (2010) Berberis vulgaris root bark extract prevents hyperoxaluria induced urolithiasis in rats. Phytotherapy Res 24:1250–1255CrossRef Bashir S, Gilani AH, Siddiqui AA, Pervez S, Khan SR, Sarfaraz NJ (2010) Berberis vulgaris root bark extract prevents hyperoxaluria induced urolithiasis in rats. Phytotherapy Res 24:1250–1255CrossRef
30.
Zurück zum Zitat Zhao F, Bergstralh EJ, Mehta RA, Vaughan LE, Olson JB, Seide BM (2016) Predictors of incident ESRD among patients with primary hyperoxaluria presenting prior to kidney failure. Clin J Am Soc Nephrol 11:119–126CrossRef Zhao F, Bergstralh EJ, Mehta RA, Vaughan LE, Olson JB, Seide BM (2016) Predictors of incident ESRD among patients with primary hyperoxaluria presenting prior to kidney failure. Clin J Am Soc Nephrol 11:119–126CrossRef
31.
Zurück zum Zitat Pottenger LH, Carney EW, Bartels MJ (2001) Dose-dependent nonlinear pharmacokinetics of ethylene glycol metabolites in pregnant (GD 10) and nonpregnant Sprague-Dawley rats following oral administration of ethylene glycol. Toxicol Scie 62:10–19CrossRef Pottenger LH, Carney EW, Bartels MJ (2001) Dose-dependent nonlinear pharmacokinetics of ethylene glycol metabolites in pregnant (GD 10) and nonpregnant Sprague-Dawley rats following oral administration of ethylene glycol. Toxicol Scie 62:10–19CrossRef
32.
Zurück zum Zitat Hatch M (2017) Gut microbiota and oxalate homeostasis. Ann Transl Med 5:36CrossRef Hatch M (2017) Gut microbiota and oxalate homeostasis. Ann Transl Med 5:36CrossRef
33.
Zurück zum Zitat Prokopovich S, Knight J, Assimos DG, Holmes RP (2007) Variability of Oxalobacter formigenes and oxalate in stool samples. J Urol 178:2186–2190CrossRef Prokopovich S, Knight J, Assimos DG, Holmes RP (2007) Variability of Oxalobacter formigenes and oxalate in stool samples. J Urol 178:2186–2190CrossRef
34.
Zurück zum Zitat Chamberlain CA, Hatch M, Garrett TJ (2019) Metabolomic profiling of oxalate-degrading probiotic Lactobacillus acidophilus and Lactobacillus gasseri. PLoS ONE 14(9):e0222393CrossRef Chamberlain CA, Hatch M, Garrett TJ (2019) Metabolomic profiling of oxalate-degrading probiotic Lactobacillus acidophilus and Lactobacillus gasseri. PLoS ONE 14(9):e0222393CrossRef
35.
Zurück zum Zitat Klimesova K, Whittamore JM, Hatch M (2015) Bifidobacterium animalis subsp. lactis decreases urinary oxalate. Urolithiasis 43:107–117CrossRef Klimesova K, Whittamore JM, Hatch M (2015) Bifidobacterium animalis subsp. lactis decreases urinary oxalate. Urolithiasis 43:107–117CrossRef
Metadaten
Titel
Oxalobacter formigenes treatment confers protective effects in a rat model of primary hyperoxaluria by preventing renal calcium oxalate deposition
verfasst von
A. Verhulst
B. Dehmel
E. Lindner
M. E. Akerman
P. C. D’Haese
Publikationsdatum
05.02.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Urolithiasis / Ausgabe 2/2022
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-022-01310-9

Neu im Fachgebiet Urologie

Genügt die biparametrische MRT für die Prostatadiagnostik?

Die multiparametrische Magnetresonanztomografie hat einen festen Platz im Screening auf klinisch signifikante Prostatakarzinome. Ob auch ein biparametrisches Vorgehen ausreicht, ist in einer Metaanalyse untersucht worden.

Große Trinkmengen bei Blasentumoren möglicherweise von Nachteil

Beim nicht-muskelinvasiven Blasenkrebs scheint eine hohe Flüssigkeitszufuhr keinen schützenden Effekt in Bezug auf das Risiko eines Rezidivs oder einer Krankheitsprogression zu haben. Eine niederländische Studie legt sogar nahe, dass große Trinkmengen das Fortschreiten der Erkrankung begünstigen könnten.

Urintest auf Prostatakrebs funktioniert mit Erststrahlurin

Ein auf die Expression von 18 Genen gestützter Urintest auf klinisch signifikanten Prostatakrebs könnte offenbar auch in Anwendung auf Erststrahlurin dazu dienen, unnötige Biopsien zu vermeiden.

Hohe Atrophierate nach Hodentorsion im Kindesalter

Auf längere Sicht ist die Atrophierate nach einer Hodentorsion pädiatrischer Patienten erschreckend hoch. Das hat eine Studie mit jahrelanger Nachbeobachtung ergeben. Entscheidend ist die Zeit, die bis zur Detorsion verstreicht.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.